United States, Oct. 20 -- The U.S. Food and Drug Administration yesterday approved the first generic of Climara Pro (estradiol and levonorgestrel transdermal system, 0.045 mg per day/0.015 mg), a transdermal hormone therapy patch for women with an intact uterus applied once a week. The approval aligns with FDA's Public Health Pillar: Increasing Access to Affordable Medicines & Medical Products. The generic estradiol and levonorgestrel transdermal system is therapeutically equivalent to Climara Pro, which is indicated for use in women with an intact uterus for:Treatment of moderate to severe vasomotor symptoms due to menopausePrevention of postmenopausal osteoporosisClimara Pro and the generic estradiol and levonorgestrel transdermal system ...